key: cord-0319531-cd718f8b
authors: Peng, W.; Rayaprolu, V.; Parvate, A.D.; Pronker, M.F.; Hui, S.; Parekh, D.; Shaffer, K.; Yu, X.; Saphire, E.O.; Snijder, J.
title: Glycan shield of the ebolavirus envelope glycoprotein GP
date: 2022-02-07
journal: bioRxiv
DOI: 10.1101/2022.02.07.479410
sha: 91291b08ac625d0df6c4344cb0f3350e2c9dd5b0
doc_id: 319531
cord_uid: cd718f8b

The envelope glycoprotein GP of the ebolaviruses is essential for host cell attachment and entry. It is also the primary target of the protective and neutralizing antibody response in both natural infection and vaccination. GP is heavily glycosylated with up to 17 predicted N-linked sites, numerous O-linked glycans in its disordered mucin-like domain (MLD), and three predicted C-linked mannosylation sites. Glycosylation of GP is important for host cell attachment to cell-surface lectins, as well as GP stability and fusion activity. Moreover, it has been shown to shield GP from neutralizing activity of serum antibodies. Here, we use mass spectrometry-based glycoproteomics to profile the site-specific glycosylation patterns of ebolavirus GP. We detect up to 16 unique O-linked glycosylation sites in the mucin-like domain, as well as two O-linked sites in the head and glycan cap domains of the receptor-binding GP1 subunit. Multiple O-linked glycans are observed at the S/T residues of N-linked glycosylation sequons, suggesting possible crosstalk between the two types of modifications. We also confirmed the presence of C-mannosylation at W288 in the context of trimeric GP. We find heterogenous, complex N-linked glycosylation at the majority of predicted sites as expected. By contrast, the two conserved sites N257 and N563 are enriched in unprocessed high-mannose and hybrid glycans, suggesting a role in host-cell attachment via DC-SIGN/L-SIGN. We discuss our findings in the context of antibody recognition to show how glycans contribute to and restrict neutralization epitopes. This information on how N-, O-, and C-linked glycans together build the heterogeneous glycan shield of GP can guide future immunological studies and functional interpretation of ebolavirus GP-antibody interactions.

We compared the pattern of predicted N-linked glycosylation sites (NXS/T) and C-mannosylation 124 sites (WXXW) of all known ebolavirus species and the related filoviruses MARV and LLOV (see 125 Figure 1A and the sequence alignment in Supplementary Figure S1 ). The number of predicted N-126 linked glycosylation sites varies from 9 in BOMV to 17 in EBOV and RESTV. Two of these 127 glycosylation sites are situated in the GP2 subunit (N563 and N618) and they are conserved in 128 all ebolavirus species, MARV and LLOV. All remaining sites are located within the GP1 subunit, 129 especially the glycan cap and MLD. Only 4 sites in GP1 are fully conserved in all ebolavirus 130 species: N40 in the base (also present in LLOV), N204 in a flexible loop between the base and 131 head domains, and N257 and N268 in the glycan cap. All other N-linked glycosylation sites in the 132 glycan cap are shared between a smaller set of ebolavirus species, but virtually all N-linked sites 133 within the MLD are unique, in line with the disordered nature and high overall sequence variability 134 of this region. There are 3 predicted C-mannosylation sites conserved in all ebolavirus species 135 and LLOV, but conspicuously missing in MARV. The first WXXW motif is situated in the glycan 136 cap, at W288 (in EBOV), close to the junction with the MLD. In addition, a tandem WXXWXXW 137 motif is situated at W645/W648 in the membrane proximal region of the GP2 subunit. 138

To visualize the N-glycan shield, we built a pseudomodel of EBOV GP with the core 139 pentasaccharide of each site linked to the corresponding residue of GP1/GP2 (see Figure 1B) . 140

The GP trimer forms a chalice-shaped structure with GP2 as the stem, and GP1 as the bowl on 141 top. The conserved sites N40, N204, N257, N268, N563 and N618 are distributed evenly across 142 the structure, whereas the remaining sites are situated primarily at the rim of the bowl extending 143 outwards from the glycan cap. The glycans occupy much of the available surface of GP. 144 Moreover, the disordered MLD connects the tip of the glycan cap with the lower base of the cup 145 and can be expected to further shield the surface of GP. This pseudo model includes only the 146 common core pentasaccharide of the N-linked glycans and it is not known how the glycans are 147 processed in the context of folded GP, as predicted sites are not always glycosylated and the 148 processing from high-mannose precursors to hybrid and mature complex glycans may depend on 149 many unpredictable factors, including local structural constraints. We investigated the patterns of 150 site-specific glycosylation of ebolavirus GP with LC-MS/MS based glycoproteomics experiments, 151 using recombinant soluble ectodomains (GPΔTM) of EBOV and BDBV, as well as the 152 corresponding full-length GP from virus-like particles produced by co-expression with VP40. We 153 compared GPΔTM from human HEK293 and insect S2 cells, both commonly used for structural 154 biology studies, experimental immunizations, antibody selection and serological tests. Our results cover 14/17 and 17/17 predicted sites in EBOV GP from HEK293 and S2 cells, 163 respectively, as well as 12/14 predicted sites of BDBV GP from both expression platforms (see 164   Figure 2 and Supplementary Table S1 ). As expected, the N-linked glycosylation patterns of GP 165 from HEK293 and S2 cells are dominated by complex and paucimannose/hybrid glycans, 166 respectively. The glycosylation of GP from especially HEK293 cells is extremely heterogeneous, 167 with some sites carrying over 40 unique glycan compositions. Predicted sites N278 and N391 in 168 BDBV were only detected as unglycosylated asparagines. Most detected glycan compositions 169 are compatible with di-, tri-and tetra-antennary, galactosylated complex glycans with or without 170 a single (core) fucose residue and a variable number of terminal sialic acids, as previously 171 described in glycomics analyses [30, 35] . While complex glycans dominate the overall picture, 172 selected sites show clear and robust enrichment of unprocessed glycans, (i.e. high-mannose and 173 hybrid structures in the HEK293-derived samples). These include particularly the conserved N257 174 and N563 sites, in both EBOV and BDBV GP. In good agreement with these observations in the 175 HEK293-derived samples, N257 and N563 are also enriched in unprocessed high-mannose 176 glycans in the S2-derived samples of both EBOV and BDBV GP, indicating that processing of 177 these sites is somehow structurally restricted. Our pseudomodel of EBOV GP indicates that N257 8 may be partially buried between the head domain and glycan cap (i.e. its first asparagine-linked 179 GlcNAc residue), and N563 similarly between the head domain and GP2. Whereas sites 180 N40/N268/N454 in EBOV GP, and N400/N454 in BDBV GP also show elevated levels of 181 unprocessed glycans in selected samples, we refrain from any conclusions on these sites due to 182 a relatively shallow coverage in the underlying mass spec data and the lack of agreement between 183 HEK293/S2 or EBOV/BDBV samples. Nevertheless, the data clearly indicate a lack of processing 184 at the conserved N257 and N563 sites in both tested ebolavirus species and expression 185 platforms. These findings are confirmed in LC-MS/MS experiments of EBOV and BDBV virus-like 186 particles derived from HEK293 cells, where we also detected a large fraction of high-mannose 187 and hybrid glycans at N257/N563 against a background of highly processed complex glycans at 188 the remaining covered sites (see Supplementary Figures S2 Our experiments also cover the C-mannosylation site at W288 in the glycan cap (see Figure 3 ). 202

The GPΔTM constructs used here are truncated before the second C-mannosylation motif at 203 W645/W648 and therefore not covered in these experiments. The GP samples derived from 204 HEK293 cells both contain a mixture of C-mannosylated and unmodified W288, with an estimated 205 occupancy of 1-10%. In contrast, this modification is completely absent in both samples derived 206 from S2 cells. The presence of C-mannosylated W288 was confirmed in the glycoproteomics 207 experiments on full-length GP in the virus-like particles formed by co-expression with VP40 (see 208

Supplementary Figure S4 ). Unfortunately, we could not detect any peptides that cover the second 209 C-mannosylation motif at W645/W648 in these samples. 210

The W288 site is situated in a lesser ordered region of the glycan cap (the β17-β18 loop) just 211 before the start of the MLD, which is deleted in the constructs of most structural studies. While 212 most available GP structures do not model the corresponding region, we identified a set of 12 213 deposited isomorphic GP crystal structures of HEK293-derived material with electron density for 214 W288 and its adjacent residues [41] [42] [43] [44] [45] . The individual crystal structures did not show a clear Fo-215

Fc density corresponding to the C2-linked mannose, but after averaging all available electron 216 density maps, a clear ring structure did appear. The weak observed electron density is consistent 217 with the low occupancy of the modification observed in our glycoproteomics experiments. The 218 C2-linked mannose residue was modelled in the extra density, positioning it at the exposed 219 surface of the glycan cap, pointing towards the center of the β17-β18 loop. 220

We also mapped out the patterns of O-linked glycosylation in ebolavirus GP (see Figure 4 ). In 

We also detected several O-glycosylation sites outside the MLD of both EBOV and BDBV GP 243 (see Figure 5 ). In BDBV GP we detected O-linked glycosylation at T280, with 6 unique glycan 244 compositions amounting to an estimated total occupancy of ~10%. This threonine residue is part 245 of a putative NPT glycosylation sequon, but we only detect the unmodified asparagine, which 246 remains unprocessed presumably because of the following proline residue. The modified 247 threonine is shared only by BDBV and TAFV GP, but absent in EBOV, SUDV, BOMV, RESTV, 248 MARV and LLOV. We also detected O-linked glycosylation at T206 in EBOV GP, with 6 unique 249 glycan compositions and an estimated occupancy of ~5%. This threonine is part of the 250 glycosylation sequon of N204, which is fully occupied by N-glycans as evidenced by the 251 deamidated asparagine and the N-linked glycoproteomics data discussed earlier. To understand the contribution of glycans to neutralization epitopes (and restrictions they impose) 272 we screened the Protein Data Bank for structural models of ebolavirus GP in complex with 273 neutralizing antibodies and also looked for linear B-cell epitopes reported in literature that span 274 the glycosylation sites we detected in our experiments (see Figure 6A ) [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] . The glycan-rich 275 epitopes we report in this overview include both cases of direct contacts between modelled GP 276 glycans and CDR residues, as well as brushing interactions of adjacent glycans with the 277 framework regions of the variable domains, which may sterically restrict binding. It should be 278 noted that glycans are typically incompletely modelled in GP-antibody structures and that 279 inference of these brushing interactions is not an exact determination. This overview indicates 280 that neutralizing antibodies span a broad range of epitopes that cover essentially all N-linked 281 glycosylation sites (N204 and the entire MLD have not yet been modelled in structural studies 282 and are therefore not represented in this analysis). The conserved GP1 glycans (N40, N257, and 283 N268) all contribute to the epitopes of neutralizing antibodies, with possible glycan-antibody 284 interactions for N268 reported in the epitopes of as many as 7 unique monoclonal antibodies. 285

This includes the therapeutic monoclonal antibody Mab114, which makes additional contacts with 286 N238. The components of the therapeutic ZMapp mixture (c2G4, c4G7 and c13C6) also interact 287 with N40, N238, N268 and N563. The epitopes of the three components in the therapeutic REGN-288 EB3 mixture are not defined to atomic detail (and therefore not included in the overview), but 289 proximity to T280 with their CDRH3 and framework 3 regions, respectively. The monoclonal 303 antibody 66-3-9c binds a linear epitope that spans the C-mannosylation site W288. Similarly, 304 c6D8 binds a linear epitope that spans the O-linked glycosylation site S399. The monoclonal 13 antibody 14G7 binds to a linear epitope in the MLD that spans the O-linked glycosylation site 306 T485. A crystal structure of the 14G7 Fab in complex with its unglycosylated epitope reveals that 307 T485 is buried deep within the cleft between heavy and light chains, where it is in direct contact 308 with CDRH3 residues (see Figure 6B ). It is therefore unlikely to accommodate the bulky O-glycans 309 detected in our experiments, further highlighting the potential epitope shielding effects of not just 310 N-glycans, but also O-glycans in the MLD. We further confirmed the presence of the C-mannosylation site in GP at W288, which is 331 completely conserved in all ebolavirus species and LLOV, but not MARV. The second motif at 332 W645/W658 is also missing in MARV, but whereas the MARV sequence at W288 completely 333 diverges from the ebolavirus species, the MARV region corresponding to W645/W648 is similarly 334 rich in tryptophan residues (see Figure 3A ). The MARV GP sequence in this region is thereby 335 primed to acquire a C-mannosylation motif through a single deletion or a tryptophan substitution 336 at any of four adjacent positions. Conversely, this could also indicate that the C-mannosylation 14 motifs were present in a common ancestor with ebolaviruses and LLOV but lost in MARV. 338

Whereas C-mannosylation is known to be important for the stability and folding of secreted human 339 glycoproteins [38, 39] , its role in ebolavirus replication and pathogenesis remains unclear. 

Ebolavirus GP sequence analysis. 400

The indicated full-length GP reference sequences were downloaded from UniProt. The LLOV-GP 401 sequence had to be reconstructed from the two separate GP1 and GP2 entries in UniProt. Structures of monoclonal antibodies in complex with ebola virus GP were retrieved from the PDB 418 (with PDB IDs: 2y6s, 3s88, 5fhc, 5kel, 5kem, 5ken, 6ea7, 6n7j, 6pci, 6qd7, 6qd8, 6s8d, 7kej, 419 7kew, 7kex, 7kfe, . The structures were aligned with the glycosylated 420 ZEBOV GP pseudomodel described above, using the MatchMaker function of ChimeraX 1.2.5, 421 and glycans within 6 Å of the CDRs or framework regions of the modelled antibodies were 422 included in the overview. 423 424

identified 12 isomorphous published crystal structures of HEK293-derived EBOV GP samples in 426 the PDB (PDB codes 6f6n, 6f6i, 6f54, 6nae, 5jqb, 5jq7, 5jq3, 6g9b, 6g9i, 6g95, 6hro and 6hs4) 427 [41] [42] [43] [44] [45] . To obtain higher signal-to-noise ratios from these maps, the 2Fo-Fc and Fo-Fc difference 428 maps were averaged using COOT [76] . This averaged map showed clear ring-shaped electron 429 density next to W288 in the Fo-Fc difference map at a contour level of 2.7 root mean square 430 deviation. A C-mannosyl group was modelled next to W288 using the EBOV GP structure 6hs4 431 as a template in COOT. To accommodate realistic geometry, the tryptophan had to be 432 repositioned slightly, albeit still in agreement with the local electron density. Care was taken to 433 model the mannose with a ring-flipped 1 C4 chair conformation [77] [78] [79] . The acquired data was analysed using Byonic (v3.9.6 [80] ) against a custom database of 515 recombinant ebola virus GP protein sequences and the proteases used in the experiment, 516 searching for glycan modifications with 12/24 ppm search windows for MS1/MS2, respectively. 517

Up to six missed cleavages were permitted using C-terminal cleavage at R/K for trypsin, R/K/E/D 518 for gluC-trypsin, or T/A/S/V for alpha lytic protease. For N-linked analysis, carbamidomethylation 20 of cysteine was set as fixed modification, oxidation of methionine/tryptophan as variable common 520 1, and hexose on tryptophan as variable rare 1. N-glycan modifications were set as variable 521 common 2, allowing up to max. 2 variable common and 1 rare modification per peptide. All N-522 linked glycan databases from Byonic were merged into a single non-redundant list to be included 523 in the database search. All reported glycopeptides in the Byonic result files were manually 524 inspected for quality of fragment assignments. All glycopeptide identifications were merged into 525 a single non-redundant list per sequon. Glycans were classified based on HexNAc content as 526 truncated (≤ 2 HexNAc; < 3 Hex), paucimannose (2 HexNAc, 3 Hex), high-mannose (2 HexNAc; 527 > 3 Hex), hybrid (3 HexNAc) or complex (> 3 HexNAc). Byonic search results were exported to 528 mzIdentML format to build a spectral library in Skyline (v20. 

Biochemical 612 analysis of the secreted and virion glycoproteins of Ebola virus

putative fusion domain of Ebola virus glycoprotein

Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-Å resolution

Proceedings of the National Academy of Sciences

Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain

SIGN mediate cellular entry by Ebola virus in cis and in trans

Differential N-linked glycosylation of human 628 immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions 629 with DC-SIGN and DC-SIGNR

DC-SIGN and DC-SIGNR bind 632 ebola glycoproteins and enhance infection of macrophages and endothelial cells

Comparison of N-and O-linked glycosylation 636 patterns of ebolavirus glycoproteins

Influences of glycosylation on antigenicity

immunogenicity, and protective efficacy of ebola virus GP DNA vaccines

N-Glycans mediate the ebola virus-GP1 shielding of ligands to 643 immune receptors and immune evasion. Frontiers in cellular and infection microbiology

Covalent modifications of the Ebola virus 646 glycoprotein

Comprehensive functional analysis of N-linked glycans on Ebola virus GP1

Identification of N-glycans from Ebola virus 652 glycoproteins by matrix-assisted laser desorption/ionisation time-of-flight and negative ion 653 electrospray tandem mass spectrometry

Devoted to the Rapid Dissemination of Up-to-the-Minute 655 Research in Mass Spectrometry

Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein 658 maturation and function

The role of 660 conserved N-linked glycans on Ebola virus glycoprotein 2. The Journal of infectious 661 diseases

Protein C-mannosylation: facts and questions. Acta 663 biochimica polonica

NetCGlyc 1.0: prediction of mammalian C-mannosylation sites

Ebola sGP-the first viral glycoprotein shown to be C-mannosylated

Discovery of Adamantane Carboxamides as 671

Ebola Virus Cell Entry and Glycoprotein Inhibitors. ACS medicinal chemistry letters

Target identification and mode of action of four 674 chemically divergent drugs against ebolavirus infection

Structure-based in silico screening identifies a potent 678 ebolavirus inhibitor from a traditional Chinese medicine library. Journal of medicinal 679 chemistry

Structures of Ebola 681 virus glycoprotein complexes with tricyclic antidepressant and antipsychotic drugs

Toremifene interacts with and destabilizes the Ebola virus 685 glycoprotein

Structural basis for a convergent immune response against Ebola Virus. Cell host & 688 microbe

A shared structural solution for 691 neutralizing ebolaviruses

Polyclonal and convergent antibody 695 response to Ebola virus vaccine rVSV-ZEBOV. Nature medicine

Cross-reactive neutralizing human survivor monoclonal 699

antibody BDBV223 targets the ebolavirus stalk

Asymmetric and Non-Stoichiometric 703

Recognition Results in Broad Protection Against Ebolaviruses by a Two-Antibody Cocktail

Structural and molecular basis for 706

Ebola virus neutralization by protective human antibodies

Convergence of a common solution for broad 710 ebolavirus neutralization by glycan cap-directed human antibodies

Structure of an Ebola virus-protective antibody in complex with 714 its mucin-domain linear epitope

Structures of Ebola virus GP and sGP in complex 717 with therapeutic antibodies

Structural basis of pan-ebolavirus neutralization by a human antibody against a 720 conserved, yet cryptic epitope

Epitopes involved in antibody-mediated protection from Ebola virus

Development of clinical-stage human 726 monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates

Global aspects of viral glycosylation

Glycosylation of viral surface proteins probed by mass 731 spectrometry. Current opinion in virology

An antibody targeting the fusion machinery neutralizes dual-734 tropic infection and defines a site of vulnerability on Epstein-Barr virus

Unexpected receptor functional mimicry elucidates 738 activation of coronavirus fusion

Site-specific glycan 740 analysis of the SARS-CoV-2 spike

Mass spectrometry-Based 742 structural virology

Molecular architecture of the SARS-CoV-2 virus

Structural principles controlling HIV envelope glycosylation

Current opinion in structural biology

Comparative analysis of the glycosylation profiles of 749 membrane-anchored HIV-1 envelope glycoprotein trimers and soluble gp140

Characterization of glycosylation profiles of HIV-1

transmitted/founder envelopes by mass spectrometry

Glycosylation patterns of HIV-1 gp120 depend on 757 the type of expressing cells and affect antibody recognition

Global mapping of O-glycosylation of varicella zoster virus, human 761 cytomegalovirus, and Epstein-Barr virus

Mass spectrometric analysis of 764

hepatitis C viral envelope protein E2 reveals extended microheterogeneity of mucin-type 765

Assessing Antigen Structural Integrity 768 through Glycosylation Analysis of the SARS-CoV-2 Viral Spike. ACS central science

Exploitation of glycosylation in 771 enveloped virus pathobiology

Clustal W and Clustal X version 2.0. 775 bioinformatics

SWISS-MODEL: homology modelling of 778 protein structures and complexes

Meeting modern challenges in visualization and analysis

Acta 783 crystallographica section D: biological crystallography

That Is C-Glycosidically Linked to the Side Chain of Tryptophan-7 in Human RNase Us Is. 786 alpha.-Mannopyranose. Biochemistry

C-Mannosylation Enhances 788 the Structural Stability of Human RNase 2. Iscience

NMR Spectroscopic Characterization of the C-Mannose Conformation in a 791

Thrombospondin Repeat Using a Selective Labeling Approach

Byonic: advanced peptide and protein identification 794 software. Current protocols in bioinformatics

The 796 Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics